Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emily Greenstein

Nurse Practitioner Fargo, ND Nurse Practitioner

NPI 1205364403 CMS profile 10429156

801 Broadway N, Fargo, ND 58102

Open in the dashboard

General payments

$270,985

308 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Greenstein of Fargo, ND is reported in the CMS Open Payments database as having received $270,985 across 308 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,247 32
2024 General $70,852 81
2023 General $71,800 93
2022 General $62,415 58
2021 General $35,671 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Greenstein
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Emily Greenstein were reported at $30,247. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Emily Greenstein Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $35,671 $135 $40–$426 $132
2022 $62,415 $152 $48–$470 $149
2023 $71,800 $166 $54–$529 $160
2024 $70,852 $173 $55–$556 $164
2025 $30,247 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. KCI USA, Inc $130,641 153 payments
  2. Solventum Corporation $100,032 102 payments
  3. Urgo Medical North America, LLC $29,818 21 payments
  4. Smith+Nephew, Inc. $4,898 18 payments
  5. Coloplast Corp $4,220 2 payments
  6. Stryker Corporation $945 3 payments
  7. Organogenesis Inc. $126 2 payments
  8. Omeza LLC $89 1 payment
  9. Paratek Pharmaceuticals, Inc. $79 1 payment
  10. Sioux Surgical Inc $57 1 payment
  11. Other $80 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $169,961 74 payments
  2. Consulting Fee $56,086 77 payments
  3. Travel and Lodging $33,990 87 payments
  4. Food and Beverage $7,373 68 payments
  5. Education $3,575 2 payments
Products named General payments · program years 2021–2025
  1. ACTIV.A.C. $103,097 92 payments
  2. 3M Cavilon $82,580 58 payments
  3. V.A.C. DERMATAC $80,832 82 payments
  4. V.A.C. VERAFLO $78,212 64 payments
  5. PROMOGRAN PRISMA $77,795 75 payments
  6. 3M Coban $72,210 63 payments
  7. PREVENA $40,446 51 payments
  8. SNAP $40,330 35 payments
  9. V.A.C. VERAFLO CLEANSE CHOICE $32,389 21 payments
  10. VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP $29,818 21 payments
  11. Other $185,340 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

59

Median for Nurse Practitioner: 389

Drug cost

$187

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 17 $126
Oxycodone Hcl Generic 16 $40
Prednisone Generic 15 $14
Meloxicam Generic 11 $7

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$12,990

Medicare's payments for the services billed

Medicare patients

199

Average age 75

Services billed

454

111 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Diabetes 53%
Chronic kidney disease 48%
Ischemic heart disease 35%
Heart failure 31%
Depression 30%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record